Ovarian Cancer Research Alliance Community Partner

RSS News

  • Partnership Improves Patient Access to Apealea Outside US August 11, 2020
    Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in areas outside the U.S. where the medication is not available. The companies have created a global named patient program, also known as an early or expanded access program, which provides physicians with a framework to legally and ethically prescribe investigational […]
  • Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result August 4, 2020
    Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would respond to treatment with PARP inhibitors — yield inconsistent results, a recent study shows. Study findings were presented in the poster “Comparison of genomic instability test […]
  • Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer July 30, 2020
    Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings from a Phase 3 trial suggest. Women who received this experimental combination in the ENGOT-ov18 trial (NCT01837251) lived significantly longer without disease progression and experienced […]
  • Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer July 28, 2020
    China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is granted in China to reduce the time to review and approve promising therapies that address urgent clinical needs. The NDA specifically covers patients with advanced ovarian, fallopian […]
  • PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer July 23, 2020
    China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. The company’s new drug application (NDA), submitted to the Center for Drug Evaluation of the Chinese National Medical Products Administration, is specifically for patients with […]
  • Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds July 21, 2020
    A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins — may improve the effectiveness of PARP inhibitors in ovarian cancers with mutations in DNA repair genes, a study in mice found. This inhibitor is a promising approach for ovarian cancers that are no longer susceptible to platinum-based chemotherapy or PARP […]
  • Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial July 16, 2020
    The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent trial shows. While the IMagyn050 Phase 3 trial (NCT03038100) failed to meet one of its primary endpoints, researchers are gathering more data to determine whether […]
  • $2.2M Awarded to Collaboration Researching Rare Form of Ovarian Cancer July 14, 2020
    A research collaboration led by the Hudson Institute of Medical Research as been awarded a $2.2-million grant to advance knowledge about ovarian granulosa cell tumors (GCT) and ultimately improve the outcomes of patients with this rare form of ovarian cancer. The multi-faceted research project will focus on mapping genetic mutations in GCTs, as well as […]
  • 3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients July 7, 2020
    An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a means to predict treatment response in women with ovarian cancer. The 3D-PREDICT trial (NCT03561207) is studying the company’s patient-specific Ex Vivo 3D Cell Culture (EV3D) […]
  • FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials June 30, 2020
    The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed treatments. The initiative is a part of the FDA’s Oncology Center of Excellence (OCE), which is designed to advance the development and regulation of oncology […]
  • Second Surgery May Aid Survival in Recurrent Ovarian Cancer, Study Finds June 30, 2020
    Woman whose ovarian cancer returns more than six months after initial surgery and chemotherapy may benefit from a second surgery, but only if the entire tumor is removed during the procedure, data from a clinical trial show. Patients should be carefully selected for a second surgery, based on the likelihood that this surgery will successfully remove […]
  • Groups Pledge Funding for Project to Develop Ovarian Cancer Blood Test June 25, 2020
    A team at Griffith University’s Institute for Glycomics in Australia has received $300,000 in funding from The Bourne Foundation, as well as a further funding pledge from Tour de Cure, to advance research into the development of blood tests for the early diagnosis of ovarian cancer. “Despite decades of research, there is currently no easily accessible, non-invasive and […]
  • Protein Biomarkers to Gauge Cancer Response to Chemo Identified June 23, 2020
    Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ovarian cancer found a wide variety of biomarkers that might help predict which chemotherapies patients are more likely to respond to, the precision medicines company mProbe reported. Identifying these tumor biomarkers is crucial not only to spotting potential targets for future therapies, but also […]
  • Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses June 18, 2020
    When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate receptor alpha (FRα), top-line data from a Phase 1b/2 trial shows. The trial findings were presented in “Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug […]
  • DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show June 16, 2020
    A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated findings from a Phase 1/2 clinical trial show. “We believe these results highlight DPX-Survivac’s potential to alter the treatment landscape in advanced ovarian cancer and […]